Comparison of HRs for progression-free survival in overall study population vs older subgroup in recent randomized trials in relapsed/refractory multiple myeloma. Endeavor trial: carfilzomib-dexamethasone vs bortezomib-dexamethasone (older subgroup ≥75, N = 143); Aspire trial: carfilzomib-lenalidomide-dexamethasone vs l lenalidomide-dexamethasone (older subgroup ≥65, N = 393); Tourmaline-1 trial: ixazomib-lenalidomide-dexamethasone (older subgroup >75, N = 108); Pollux trial: daratumumab-bortezomib-dexamethasone vs bortezomib-dexamethasone (older subgroup ≥75, N = 64); Castor trial: daratumumab-lenalidomide-dexamethasone vs lenalidomide-dexamethasone (older subgroup ≥65, N = 241); Eloquent-2 trial: elotuzumab-lenalidomide-dexamethasone vs lenalidomide-dexamethasone alone (older subgroup ≥65, N = 370); Panorama trial: panobinostat-bortezomib-dexamethasone vs bortezomib-dexamethasone (older subgroup ≥65, N = 323); OptimisMM trial: pomalidomide-bortezomib-dexamethasone vs bortezomib-dexamethasone (no subgroup analysis published); and Eloquent-3 trial: elotuzumab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone alone (no subgroup analysis published).